NASDAQ:PCVX Vaxcyte - PCVX News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $37.70 -0.18 (-0.48%) (As of 03/24/2023 01:45 PM ET) Add Compare Share Share Today's Range$37.35▼$37.9550-Day Range$37.08▼$46.8952-Week Range$17.44▼$49.31Volume155,175 shsAverage Volume659,038 shsMarket Capitalization$3.02 billionP/E RatioN/ADividend YieldN/APrice Target$64.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Media Mentions By Week PCVX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCVX News Sentiment▼0.580.35▲Average Medical News Sentiment PCVX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCVX Articles This Week▼01▲PCVX Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVaxcyte, Inc. (NASDAQ:PCVX) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 13 at 4:55 AMVaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatefinanznachrichten.de - March 1 at 8:25 AMVaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 1 at 8:25 AMVaxcyte GAAP EPS of -$3.44 misses by $0.11msn.com - March 1 at 8:25 AMNeedham Keeps Their Buy Rating on Vaxcyte (PCVX)markets.businessinsider.com - March 1 at 8:25 AMPreview: Vaxcyte's Earningsbenzinga.com - February 24 at 4:00 PMVaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infantsfinance.yahoo.com - February 21 at 11:08 AMVaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023finance.yahoo.com - February 16 at 7:22 PMVaxcyte to Present at the SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 7 at 8:49 PMVaxcyte: Behind The Recent Rallyseekingalpha.com - January 16 at 7:51 AMThis Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analystfinance.yahoo.com - January 3 at 5:39 PMSutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extractfinance.yahoo.com - December 20 at 5:58 PMVaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Updatetechnews.tmcnet.com - November 8 at 6:31 PMVaxcyte Has A Bright Future Aheadseekingalpha.com - November 2 at 3:24 PMVaxcyte, Inc.'s (NASDAQ:PCVX) large institutional owners must be happy as stock continues to impress, up 111% over the past weekfinance.yahoo.com - October 30 at 6:49 PMWhy Shares of Vaxcyte Rose 110.7% This Weekfinance.yahoo.com - October 29 at 1:56 PMVaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Sharesbenzinga.com - October 28 at 6:41 PMVaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Sharesfinance.yahoo.com - October 28 at 6:41 PMVaxcyte (PCVX) Has Rallied 70% This Week on Trial Results. Is There More Upside?247wallst.com - October 26 at 5:21 PMVaxcyte Announces Pricing of $600 Million Public Offeringfinance.yahoo.com - October 26 at 2:18 AMVaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrantsfinance.yahoo.com - October 25 at 11:03 AMVaccine developer Vaxcyte stock soars on results of experimental pneumonia jabfinance.yahoo.com - October 25 at 11:03 AMRecent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Whyfinance.yahoo.com - October 25 at 11:03 AMHow Is The Market Feeling About Vaxcyte?msn.com - October 24 at 12:49 PMVaxcyte climbs 38% after proof-of-concept data for pneumococcal vaccineseekingalpha.com - October 24 at 12:49 PMBill Gates' Big Vaccine Bet Might Beat Pfizerthestreet.com - October 24 at 12:49 PMVaxcyte Shares Are Soaring: Here's Whymarkets.businessinsider.com - October 24 at 12:49 PMVaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adultsfinance.yahoo.com - October 23 at 8:49 PMVaxcyte Expands Executive Leadership Team with Key Appointmentsfinance.yahoo.com - October 11 at 8:32 PMVaxcyte (PCVX) Shares Cross Below 200 DMAnasdaq.com - October 4 at 3:48 PMNeedham Reaffirms Their Buy Rating on Vaxcyte (PCVX)markets.businessinsider.com - September 28 at 10:47 AMVaxcyte Completes Enrolment In Mid-Stage Pneumococcal Disease Study, Sees Top-line Data In H1 2013markets.businessinsider.com - September 6 at 6:33 PMVaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Olderfinance.yahoo.com - September 6 at 6:33 PMWe're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wiselyfinance.yahoo.com - August 15 at 7:09 AMVaxcyte (PCVX) Investor Presentation - Slideshowseekingalpha.com - August 13 at 7:13 PMVaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - August 8 at 6:56 PMVaxcyte wins FDA’s Fast Track designation for pneumococcal vaccine candidateseekingalpha.com - August 4 at 1:03 PMVaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programsfinance.yahoo.com - August 4 at 1:02 PMVaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Studyfinance.yahoo.com - July 14 at 2:37 PMVaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Studymarkets.businessinsider.com - July 12 at 8:39 PMVaxcyte to Present at the Jefferies Healthcare Conferencefinance.yahoo.com - June 2 at 7:14 PMPCVX Makes Bullish Cross Above Critical Moving Averagenasdaq.com - May 13 at 3:24 PMVaxcyte Reports First Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - May 9 at 6:37 PMCould The Vaxcyte, Inc. (NASDAQ:PCVX) Ownership Structure Tell Us Something Useful?finance.yahoo.com - May 4 at 2:33 PMVaxcyte to Participate in Upcoming Investor Conferences in Maynz.finance.yahoo.com - May 3 at 9:48 AMVaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 5 at 1:17 PMVaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adultsfinance.yahoo.com - April 4 at 11:41 AMCompanies Like Vaxcyte (NASDAQ:PCVX) Are In A Position To Invest In Growthfinance.yahoo.com - March 8 at 8:28 AMVaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updatefinance.yahoo.com - February 28 at 5:43 PMVaxcyte doses first patients in phase 1/2 trial of pneumonia vaccineseekingalpha.com - February 24 at 9:22 AM Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:PCVX) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.